At present, most medical reforms adopt methods such as restricting drug prices and payment links. In the face of hospital information islands, there is not enough big data to support it. It is difficult to really touch the core contradictions. The rise of medical big data technology has made it possible to audit smart medical insurance fees, which has spawned a market of up to 100 billion.
Due to technical and maintenance capabilities, government agencies do not have the ability to build and maintain a big data intelligence auditing system. Therefore, the adoption of the PPP model, the introduction of professional companies with medical information background, joint construction of intelligent monitoring of third-party service platforms, has gradually become the mainstream of the industry.
In the face of the emerging market, Huaxuekang has successfully established cooperation with many provinces and cities in Xinjiang, including Inner Mongolia, Inner Mongolia, Shaanxi, Sichuan, Fujian and Guangdong in just two years. The market leader in the medical insurance intelligent control industry.
How does Huashukang use big data technology to assist the Ministry of Human Resources and Social Security and insurance companies to achieve control fees? With questions, the arterial network exclusive interview with Dr. Chen Chen, Chief Information Officer (CIO) of Huaxuankang.
.jpg)
Using big data to intervene in medical insurance control fees
Medical insurance has absolute control over funds. Based on this, medical insurance can be used to promote the reform of medical and pharmaceutical products, so as to achieve the goal of triple medical linkage. Qi Chen believes: "As the only quantifiable part of the 'three medical doctors', medical insurance is the core point of cutting into medical reform. The quality of service of medical institutions makes it difficult for patients to weigh, and in addition to controlling prices, the government has no better control measures. But medical insurance is different. As a quantifiable fund, once the deficit increases, it will quickly awaken the government's sense of crisis. It is a good fit to promote medical reform."
"We found that because the level of medical insurance is too low, many of them are only co-ordinated in prefecture-level cities and even county-level units. As a result, the problem of medical custody control has caused people to take great pressure on medical insurance expenditures. The medical insurance fund has become a normal state." This morning, I told the arterial network.
After discovering this problem, Dr. Chen Chen, who is born in data technology, is determined to help the government change the status quo through big data. Founded in 2014, Beijing Huaxuankang Data Technology Co., Ltd., a technology-based company, focuses on the big health industry and is a provider of big data solutions for medical insurance, business insurance, medical care and medicine.
After fully understanding and comparing the products of many competitors in the industry, Dr. Chen Chen and the R&D team developed a complete RWE+ big data solution, including two subsystem platforms, HCS and PROBIT, which integrate software, hardware and large. Data application is one, which can resolve the contradiction between the medical insurance department and the hospital in the process of controlling the fees, and solve the shortcomings of the low level of medical insurance coordination at the data interaction level.
Intermediate – Intermediate: A material produced during a drug substance processing step that must undergo further molecular modification or refinement to become a drug substance. Intermediates may or may not be isolated. Intermediates are the key products of the previous process of making APIs, which are different in structure from APIs.
for example:
Amoxicillin capsules are called preparations, amoxicillin is called API, and 6-APA is called intermediate.
Ceftriaxone sodium powder is called preparation, sterile ceftriaxone sodium is called API, and 7-ACA is called intermediate.
Our company specializes in providing key intermediates for various APIs
Intermediate is a very important type of fine chemical products. Its essence is a type of "semi-finished product", which is an intermediate product in the production of certain products. For example, if a product is to be produced, it can be produced from intermediates, saving costs and reducing It is widely used in the synthesis of medicines, pesticides, coatings, dyes and spices. In the field of medicine, intermediates are an important link in the industrial chain of the pharmaceutical industry. They are used for some chemical raw materials or chemical products in the process of drug synthesis. In a word, they are used to produce APIs.
Key Intermediates , Pharmaceutical intermediates , Anticancer intermediates , Antitumor Intermediates
XI AN RHINE BIOLOGICAL TECHNOLOGY CO.,LTD , https://www.xianrhinebiotech.com